Start-up Erasca has launched with $42m of series A funding. The company is a startup accelerator that helps startups raise money and build their businesses. It describes its goal as not just treating cancer, but eradicating residual disease, using numerous therapeutic modalities, including combination therapies.
Start-up Erasca has launched with $42m of series A funding. The San Diego-based pharmaceutical company said it aims to concentrate initially on small-molecule drugs for the treatment of solid tumours. It describes its goal as not just treating cancer, but eradicating residual disease, using numerous therapeutic modalities, including combination therapies.